PDCD1 and neoplasm: TMB is a reliable indicator of predicted clinical efficacy of the PD-1 inhibitor (Jafarnejad et al., 2019); the more mutant genes in the tumor tissue, the more likely it is that abnormal proteins will be significantly produced.